LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Kodu・Aktsiate loetelu・Heron Therapeutics Inc

Heron Therapeutics Inc

Suletud

SektorTervishoid

0.42 -10.64

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.42

Max

0.48

Põhinäitajad
By Trading Economics
Sissetulek	-5.2M -8.1M
Müük	-5.9M 35M
Aktsiakasum	-0.04
Kasumimarginaal	-23.367
Töötajad	128
EBITDA	-4M -4.8M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+316.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-74M 157M
Eelmine avamishind	11.06
Eelmine sulgemishind	0.42

Uudiste sentiment

By Acuity

70%

30%

300 / 344 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. juuni 2026, 21:51 UTC

Suurimad hinnamuutused turgudel

Merlin Shares Rally After Defense Department's Design Review Wraps

4. juuni 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4. juuni 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4. juuni 2026, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4. juuni 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Energy Resources of Australia to Enter Trading Halt

4. juuni 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4. juuni 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4. juuni 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. juuni 2026, 20:44 UTC

Omandamised, ülevõtmised, äriostud

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4. juuni 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4. juuni 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4. juuni 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4. juuni 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4. juuni 2026, 18:47 UTC

Omandamised, ülevõtmised, äriostud

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4. juuni 2026, 18:38 UTC

Tulu

Money Quote: Tech Weakness in Context -- WSJ

4. juuni 2026, 18:24 UTC

Tulu

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4. juuni 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4. juuni 2026, 16:58 UTC

Tulu

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4. juuni 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4. juuni 2026, 16:38 UTC

Tulu

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4. juuni 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4. juuni 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4. juuni 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4. juuni 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

316.67% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 316.67%

Kõrge 2 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Heron Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

300 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.